Manifestaciones clínicas y anticuerpos asociados y específicos de miositis en 15 pacientes chilenos con dermatomiositis: serie clínica en un centro universitario

Abstract

Clinical manifestations and antibody profile in 15 patients with dermatomyositis Background: Certain associated and specific myositis antibodies are related to certain clinical phenotypes of dermatomyositis (DM), disease severity and the presence of cancer. Aim: To describe the clinical profile of Chilean patients with DM and their associated and specific myositis antibodies. Material and Methods: Review of medical records of 15 patients with DM aged 31 to 72 years. Their clinical characteristics, laboratory tests and complementary tests were reviewed. In serum samples from each patient the presence of 16 specific antibodies was analyzed by immunoblot technique (Myositis Profile Euroline Blot test kit). Results: Fourteen (93.3%) patients had skin manifestations, five (33.3%) had pulmonary involvement, two (13.3%) had an associated cancer and nine (60%) had specific antibodies associated with myositis. Conclusions: These patients with DM had a clinical profile similar to what has been described elsewhere. The profile of myositis specific antibodies was different from reports in other populations.

Characterization of Patients With Dermatomyositis According to Anti–Melanoma Differentiation-Associated Gene-5 Autoantibodies in Centers from 3 Latin American Countries

“…Corroborating data from the literature, 10,11,[18][19][20][21][22][23][24][25][26][27] DM mainly affected females. Furthermore, in the present study, there was a predominance of mestizo and White ethnicities.…”

“…RP-ILD represents approximately 22% of all cases of ILD in patients with DM, 18,21,[23][24][25] but the prevalence of RP-ILD can reach 75% of all cases of ILD in Asian populations. 10,11 Studies in Latin American centers have observed a prevalence of ILD ranging from 16.5% to 33.3%, 21,26,27 and none of these studies has reported cases of RP-ILD. The most striking feature in the present study is the low frequency of RP-ILD (1.5%); therefore, our study corroborates the few studies available that were conducted with individuals from Latin American countries.…”

“…Studies in Latin American centers have observed a prevalence of ILD ranging from 16.5% to 33.3%, 21,26,27 and none of these studies has reported cases of RP-ILD. The most striking feature in the present study is the low frequency of RP-ILD (1.5%); therefore, our study corroborates the few studies available that were conducted with individuals from Latin American countries 21,26,27 …”

“…The most striking feature in the present study is the low frequency of RP-ILD (1.5%); therefore, our study corroborates the few studies available that were conducted with individuals from Latin American countries. 21,26,27 In addition to supportive treatment with oxygen and/or mechanical ventilation, there is no consensus on specific immunosuppressive treatment for RP-ILD patients. 10,11,13,22,24 All our RP-ILD patients used systemic glucocorticoids and 75% used 3 or more immunosuppressants.…”

“…10,11,19,20 Studies in Latin American countries have not described RP-ILD cases in DM patients. 21,26,27 In summary, the characteristics of DM patients seem to vary according to clinical and laboratory features, DM subgroup, and geographic region. In Latin America, the frequency of RP-ILD appears to be lower than in other countries.…”